Association of a common AKAP9 variant with breast cancer risk: A collaborative analysis

Journal of the National Cancer Institute

Volumn 100, Issue 6, 2008, Pages 437-442

  Frank, Bernd ^a   Wiestler, Miriam ^a   Kropp, Silke ^a   Hemminki, Kari ^a,b   Spurdle, Amanda B ^c   Sutter, Christian ^d   Wappenschmidt, Barbara ^e,f   Chen, Xiaoqing ^c   Beesley, Jonathan ^c   Hopper, John L ^g   Meindl, Alfons ^h   Kiechle, Marion ^h   Slanger, Tracy ^a   Bugert, Peter ^d   Schmutzler, Rita K ^e,f   Bartram, Claus R ^d   Flesch Janys, Dieter ⁱ   Mutschelknauss, Elke ⁱ   Ashton, Katie ^a   Salazar, Ramona ^j   Webb, Emily ^k   Hamann, Ute ^a   Brauch, Hiltrud ^l   Justenhoven, Christina ^l   Ko, Yon Dschun ^m   Brüning, Thomas ⁿ   Dos Santos Silva, Isabel ^o   Johnson, Nichola ^k   Pharoah, Paul P D ^p   Dunning, Alison M ^p   Pooley, Karen A ^p   Chang Claude, Jenny ^a   Easton, Douglas F ^p   Peto, Julian ^k,o   Houlston, Richard ^k   Chenevix Trench, Georgia ^c   Fletcher, Olivia ^k   Burwinkel, Barbara ^a   Bowtell, David ^c,q   Green, Adele ^c,q   Webb, Penny ^c,q   DeFazio, Anna ^c,q   Gertig, Dorota ^c,q   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j Bioglobe GmbH   (Germany)

^k INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m Johanniter Krankenhaus   (Germany)

ⁿ RUHR UNIVERSITY BOCHUM   (Germany)

^o LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^q PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; AKAP9 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; ISOLEUCINE; METHIONINE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EUROPE; FAMILIAL CANCER; GENE DELETION; GENE DOSAGE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN VARIANT; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; BREAST TUMOR; CASE CONTROL STUDY; CAUCASIAN; FEMALE; GENETIC PREDISPOSITION; GENETICS; GERMANY; META ANALYSIS; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

A KINASE ANCHOR PROTEINS; ADULT; AGED; ALLELES; AUSTRALIA; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOSKELETAL PROTEINS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; ISOLEUCINE; LINKAGE DISEQUILIBRIUM; METHIONINE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 41449096590     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn037     Document Type: Article

References (47)

1. Baselga J, Norton L. Focus on breast cancer. Cancer Cell. 2002;1(4):319-322.
2. Meindl A; German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002;97(4):472-480.
3. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31(1):33-36.
4. Johnson N, Fletcher O, Palles C, et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet. 2007;16(9):1051-1057.
5. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087-1093.
6. Ralhan R, Kaur J, Kreienberg R, Wiesmüller L. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett. 2007;248(1):1-17.
7. Frank B, Hemminki K, Meindl A, et al. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer. 2007;7:83.
8. Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene. 2004;23(38):6471-6476.
9. Justenhoven C, Hamann U, Schubert F, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway [published online ahead of print June 23, 2007; PMID: 17588204]. Breast Cancer Res Treat.
10. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005;97(12):755-765.
11. Burwinkel B, Wirtenberger M, Klaes R, et al. Association of NCOA3 polymorphisms with breast cancer risk. Clin Cancer Res. 2005;11(6):2169-2174.
12. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol. 2007;19(2):192-198.
13. Langeberg LK, Scott JD. A-kinase-anchoring proteins. J Cell Sci. 2005;118(Pt 15):3217-3220.
14. Miller WR. Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci. 2002;968:37-48.
15. Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol. 1995;21(1-3):33-61.
16. Tortora G, Ciardiello F. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann N Y Acad Sci. 2003;1002:236-243.
17. Kammerer S, Burns-Hamuro LL, Ma Y, et al. Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci USA. 2003;100(7):4066- 4071.
18. Tingley WG, Pawlikowska L, Zaroff JG, et al. Gene-trapped mouse embryonic stem cell-derived cardiac myocytes and human genetics implicate AKAP10 in heart rhythm regulaion. Proc Natl Acad Sci USA. 2007;104(20):8461-8466.
19. Wirtenberger M, Schmutzhard J, Hemminki K, et al. The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis. 2007;28(2):423-426.
20. Sharma S, Qian F, Keitz B, et al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2005;99(1):183-188.
21. Webb EL, Rudd MF, Sellick GS, et al. Search for low penetrance alleles for colorectal cancer through a scan of 1467 nonsynonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 firstdegree relatives. Hum Mol Genet. 2006;15(21):3263-3271.
22. Rudd MF, Webb EL, Matakidou A, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 2006;16(6):693-701.
23. Garnis C, Rosin MP, Zhang L, Lam WL. Alteration of AKAP220, an upstream component of the Rb pathway, in oral carcinogenesis. Int J Cancer. 2005;116(5):813-819.
24. Choi MC, Jong HS, Kim TY, et al. AKAP12/ Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene. 2004;23(19):7095-7103.
25. Lewis TE, Milam TD, Klingler DW, et al. Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer. Urol Oncol. 2005;23(6):407-412.
26. Wirtenberger M, Tchatchou S, Hemminki K, et al. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis. 2006;27 (3):593-598.
27. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet. 2006;7:61-80.
28. Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst. 2003;95 (6):448-457.
29. Hopper JL, Giles GG, McCredie MRE, Boyle P. Background, rationale and protocol for a case-control-family study of breast cancer. Breast. 1994;3:79-86.
30. Fletcher O, Johnson N, Palles C, et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2006;98(14):1014-1018.
31. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood. 2006;108(2):638-644.
32. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol. 2005;20(8):699-711.
33. Frank B, Bermejo JL, Hemminki K, et al. Re: association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2005;97(13):1012.
34. Johnatty SE, Spurdle AB, Beesley J, et al. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies [published online ahead of print June 26, 2007]. Breast Cancer Res Treat.
35. Gayther SA, Song H, Ramus SJ, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2007;67(7):3027-3035.
36. Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFaB familial breast cancer resource. Breast Cancer Res. 2006;8(1):R12.
37. Baynes C, Healey CS, Pooley KA, et al. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res. 2007;9(2):R27.
38. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113-1124.
39. Day N, Oakes S, Luben R, et al. EPICNorfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(suppl 1): 95-103.
40. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol. 2003;25(3):190-202.
41. Frank B, Hemminki K, Wirtenberger M, et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005;26(3):643-647.
42. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265.
43. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007;39(3):352-358.
44. Xi T, Jones IM, Mohrenweiser HW. Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics. 2004;83(6):970-979.
45. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115(1):94-101.
46. Fusco A, Viglietto G, Santoro M. A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest. 2005;115(1):20-23.
47. Lee JH, Lee ES, Kim YS, Won NH, Chae YS. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 2006;38(3):201-204.